Table 4 Prescription changes in the pharmacist intervention and non-intervention groups during January–December 2017
Intervention group (n = 132) | Non-intervention group (n = 264) | P-values | ||
|---|---|---|---|---|
Prescription changes for all medications | 94 (71.2%) | 111 (42.0%) | < 0.001 | |
Prescription changes for antithrombotic drugs | 42 (31.8%) | 45 (17.0%) | 0.001 | |
Warfarin | Total changes | 22 (16.7%) | 32 (12.1%) | 0.22 |
Dose adjustments | 21 (15.9%) | 32 (12.1%) | 0.35 | |
Discontinuations | 1 (0.8%) | 0 | 0.33 | |
Drug changes | 0 | 0 | 1.00 | |
Initiations | 0 | 0 | 1.00 | |
DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) | Total changes | 6 (4.5%) | 8 (3.0%) | 0.56 |
Dose adjustments | 1 (0.7%) | 1 (0.4%) | 1.00 | |
Discontinuations | 1 (0.7%) | 1 (0.4%) | 1.00 | |
Drug change | 4 (3.0%) | 5 (1.9%) | 0.49 | |
Initiation | 0 | 1 (0.4%) | 1.00 | |
Antiplatelet (aspirin, clopidogrel, prasugrel, cilostazole, etc.) | Total changes | 14 (10.6%) | 5 (1.9%) | < 0.001 |
Dose adjustment | 0 | 0 | 1.00 | |
Discontinuations | 11 (8.3%) | 4 (1.5%) | 0.001 | |
Drug change | 3 (2.3%) | 1 (0.4%) | 0.11 | |
Initiation | 0 | 0 | 1.00 | |